Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,607.98 91.71 0.63%
TOPIX 1,178.17 4.80 0.41%
HANG SENG 22,760.24 64.23 0.28%

Supernus Launches Trokendi XR(TM) in the United States



Supernus Launches Trokendi XR(TM) in the United States

ROCKVILLE, Md., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that
Trokendi XR™ is now available to patients in the United States. Trokendi XR is
a novel once-daily extended release formulation of topiramate for the
treatment of epilepsy. The product has been shipped to major wholesalers in
the market, and the Company's sales force is promoting the product to
physicians.

"We have built our sales force from the ground up, and this is our second
product launch this year, representing a remarkable achievement for Supernus.
Supernus is now a major player in epilepsy, offering two novel and
differentiated products to patients. The Company continues its long standing
heritage of excellence in execution against its corporate goals. I would like
to take this opportunity to thank all Supernus employees for their hard work
and dedication that allowed us to launch Trokendi XR very shortly after
receiving FDA approval," said Jack Khattar, President & CEO, of Supernus.

About Trokendi XR™

Trokendi XR is a novel once-daily extended release formulation of topiramate.
Trokendi XR is an antiepileptic drug indicated for initial monotherapy in
patients 10 years of age and older with partial onset or primary generalized
tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older
with partial onset or primary generalized tonic-clonic seizures; and
adjunctive therapy in patients 6 years of age and older with seizures
associated with Lennox-Gastaut syndrome. The product is available in 25mg,
50mg, 100mg and 200mg extended-release capsules.

For full prescribing and safety information, click here.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR™ (extended-release oxcarbazepine) and Trokendi XR™
(extended-release topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in ADHD,
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Forward Looking Statements

This press release contains forward-looking statements regarding the potential
for Trokendi XR to treat epilepsy and the timing of the product's availability
to physicians. Actual results may differ materially from those in these
forward-looking statements as a result of various factors, including, but not
limited to, risks regarding the company's ability to commercialize the product
successfully, whether physicians will prescribe and patients will use the
product, once available, and competition in the market. For a further
description of these and other risks facing the Company, please see the risk
factors described in the Company's Annual Report Form on 10-K that was filed
with the United States Securities and Exchange Commission on March 15, 2013
and under the caption "Risk Factors" and the updates to these risk factors in
the Company's quarterly report on Form 10-Q that was filed with the Commission
on August 14, 2013. Forward-looking statements speak only as of the date of
this press release, and the Company undertakes no obligation to update or
revise these statements, except as may be required by law.

CONTACT: Jack A. Khattar, President and CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement